Reimbursement In Brief
CMS drops reimbursement code for off-label Avastin use ahead of schedule: On Nov. 16, CMS formally drops the Q-code it had set up to reimburse physicians outside of the hospital setting for off-label use of Avastin (bevacizumab) to treat wet aged macular degeneration. The agency previously announced the Q-code would be dropped on Jan. 1, 2010 (1"The Pink Sheet" DAILY, Oct. 28, 2009). The Q-code generated controversy because it would under-reimburse physicians who use the drug over Lucentis (ranibizumab), which is approved for the indication but is significantly more expensive. Both drugs are manufactured by Roche/Genentech
You may also be interested in...
Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.
Agency backs down from changes proposed in July, in part because of provisions in recently passed FDA reform act.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011